Legendary game show host Wink Martindale passed away at 91 due to lymphoma Learn about lymphoma’s warning signs and the ...

CAR T cells have been highly successful in individuals with B cell leukemia/lymphoma and multiple myeloma (MM). However, most of the CAR T cell targets currently in clinical trials for AML are ...

PRESENTED at EBMT 2025 Annual Meeting, a new study explored the long-term effectiveness of chimeric antigen receptor (CAR)-T cell cocktail therapy for patients with relapsed/refractory diffuse large B ...

we found that these tumor cells were all positive for the T-cell antigens CD2 and CD3 and negative for CD8 and CD56. Particularly, the lymphoma cells were positive for CD20 while other B-cell antigens ...

SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

or CAR T cell therapy, where a patient's immune cells are taken out, grown and modified to specifically target certain cancers such as the aggressive lymphoma Cannella had. When he was first ...

Neoplastic cell morphology in peripheral blood (A) and bone marrow aspirate films (B) showing small- to medium-sized lymphoplasmacytic lymphocytes (May Grunwald Giemsa stain, 1000×). Bone marrow ...

This trial enrolled 37 adult patients with CD30-positive Hodgkin lymphoma and five with T-cell lymphoma. Patients were heavily pretreated and were refractory to brentuximab vedotin and anti-PD1 ...

More information: Yago Nieto et al, Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial, Nature Medicine (2025). DOI: 10.1038/s41591-025 ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted clearance to initiate a global ...

In addition, a long-term follow-up analysis of a phase III study showed that 29% of patients in a watch-and-wait group still didn't need therapy ... non-Hodgkin lymphoma or mantle cell lymphoma ...